Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2008

01-10-2008 | Original Article

Proteinuria and decreased body mass index as a significant risk factor in developing end-stage renal disease

Authors: Kunitoshi Iseki, Kaori Tokashiki, Chiho Iseki, Kentaro Kohagura, Kozen Kinjo, Shuichi Takishita

Published in: Clinical and Experimental Nephrology | Issue 5/2008

Login to get access

Abstract

Background

Body mass index (BMI) is a significant predictor of developing end-stage renal disease (ESRD). The relation between a change in BMI (ΔBMI) and the incidence of ESRD has not been examined in any large epidemiologic studies.

Methods

We determined the ΔBMI in subjects who participated in the Okinawa General Health Maintenance Association (OGHMA) screenings in 1983 and again in 1993. Screenees were free of ESRD at the 1993 screening and were then monitored until the end of 2000 to determine whether they developed ESRD. Participants were identified using ID numbers, birthdates, and other identifiers. Details of every ESRD patient treated in Okinawa are maintained in an independent community-based dialysis registry. Multivariate logistic analyses were performed to determine the significance of a ΔBMI on the incidence of ESRD using SAS. The ethics committee of the OGHMA approved the study protocol. Only coded data were used for this study.

Results

Among the 92,364 subjects aged 30–89 years screened in 1983, 29,011 (31.4%) returned for the 1993 screening. The median ΔBMI was 2.1%, and the subjects were divided into two groups: ΔBMI < 2.1% (G1) and ΔBMI ≥ 2.1% (G2). The cumulative incidence of ESRD was 0.31% in G1 (ESRD in 44) and 0.14% in G2 (ESRD in 21). The odds ratio (95% confidence interval) of developing ESRD based on a ΔBMI was 2.268 (1.284–4.000, P < 0.01) after adjusting for age, sex, systolic blood pressure, BMI in 1983, and proteinuria.

Conclusion

The findings of the present study suggest that a ΔBMI is an independent risk factor for the incidence of ESRD, especially for those with proteinuria. The reasons for the BMI change were not recorded in this study. Unintentional weight loss, however, might warrant evaluation for the presence or progression of chronic kidney disease.
Literature
2.
go back to reference US Renal Data System. USRDS 2006 Annual Data Report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis. 2008;51 Suppl 1:S81–98. US Renal Data System. USRDS 2006 Annual Data Report: atlas of end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis. 2008;51 Suppl 1:S81–98.
3.
go back to reference Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am. 2003;32:741–60.CrossRef Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am. 2003;32:741–60.CrossRef
4.
go back to reference Iseki K, Kohagura K, Iseki C, et al. Changes in demographics and the prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res. 2007;30:55–62.CrossRef Iseki K, Kohagura K, Iseki C, et al. Changes in demographics and the prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003). Hypertens Res. 2007;30:55–62.CrossRef
5.
go back to reference Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870–6.CrossRef Iseki K, Ikemiya Y, Kinjo K, et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004;65:1870–6.CrossRef
6.
go back to reference Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–8.CrossRef Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–8.CrossRef
7.
go back to reference Sowers JR. Metabolic risk factors and renal disease. Kidney Int. 2007;71:719–20.CrossRef Sowers JR. Metabolic risk factors and renal disease. Kidney Int. 2007;71:719–20.CrossRef
8.
go back to reference Krikken JA, Lely AT, Bakker SJ, et al. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int. 2007;71:260–5.CrossRef Krikken JA, Lely AT, Bakker SJ, et al. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int. 2007;71:260–5.CrossRef
9.
go back to reference Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.CrossRef Fox CS, Larson MG, Leip EP, et al. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.CrossRef
10.
go back to reference Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140:167–74.CrossRef Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140:167–74.CrossRef
11.
go back to reference Stengel B, Tarver-Carr ME, Powe NR, et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14:479–87.PubMed Stengel B, Tarver-Carr ME, Powe NR, et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology. 2003;14:479–87.PubMed
12.
go back to reference Metcalf P, Baker J, Scott A, et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension, and hyperlipidemia. Clin Chem. 1992;38:1802–8.PubMed Metcalf P, Baker J, Scott A, et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension, and hyperlipidemia. Clin Chem. 1992;38:1802–8.PubMed
13.
go back to reference Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.CrossRef Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.CrossRef
14.
go back to reference Tanaka H, Shiohira Y, Uezu Y, et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69:369–74.CrossRef Tanaka H, Shiohira Y, Uezu Y, et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69:369–74.CrossRef
15.
go back to reference Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–40.CrossRef Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–40.CrossRef
16.
go back to reference Praga M, Hernandez E, Andres A, et al. Effects of body weight loss and captopril treatment on proteinuria associated with obesity. Nephron. 1995;70:35–41.CrossRef Praga M, Hernandez E, Andres A, et al. Effects of body weight loss and captopril treatment on proteinuria associated with obesity. Nephron. 1995;70:35–41.CrossRef
17.
go back to reference Tozawa M, Iseki K, Iseki C, et al. Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002;62:956–62.CrossRef Tozawa M, Iseki K, Iseki C, et al. Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002;62:956–62.CrossRef
18.
go back to reference Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a Southeast Asian population: a 12-year cohort study. J Am Soc Nephrol. 2005;16:791–9.CrossRef Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a Southeast Asian population: a 12-year cohort study. J Am Soc Nephrol. 2005;16:791–9.CrossRef
19.
go back to reference Kopple JD, Greene T, Chumlea WC, et al. Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int. 2000;57:1688–703.CrossRef Kopple JD, Greene T, Chumlea WC, et al. Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int. 2000;57:1688–703.CrossRef
20.
go back to reference Chertow GM, Hsu C, Johansen KL. The enlarging body of evidence: obesity and chronic kidney disease. J Am Soc Nephrol. 2006;17:1501–2.CrossRef Chertow GM, Hsu C, Johansen KL. The enlarging body of evidence: obesity and chronic kidney disease. J Am Soc Nephrol. 2006;17:1501–2.CrossRef
21.
go back to reference Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk of chronic renal failure. J Am Soc Nephrol. 2006;17:1695–702.CrossRef Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk of chronic renal failure. J Am Soc Nephrol. 2006;17:1695–702.CrossRef
22.
go back to reference Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol. 2006;17:1453–9.CrossRef Kramer HJ, Saranathan A, Luke A, et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol. 2006;17:1453–9.CrossRef
23.
go back to reference Iseki K, Iseki C, Ikemiya Y, et al. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800–5.CrossRef Iseki K, Iseki C, Ikemiya Y, et al. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800–5.CrossRef
24.
go back to reference Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18:1540–6.CrossRef Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18:1540–6.CrossRef
25.
go back to reference Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006;17:2974–84.CrossRef Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006;17:2974–84.CrossRef
26.
go back to reference Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRef Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.CrossRef
27.
go back to reference Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–95.CrossRef Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–95.CrossRef
28.
go back to reference Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264–71.CrossRef Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264–71.CrossRef
29.
go back to reference Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;69:228–36.CrossRef Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;69:228–36.CrossRef
30.
go back to reference Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11:41–50.CrossRef Imai E, Horio M, Nitta K, et al. Estimation of glomerular filtration rate by the MDRD equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol. 2007;11:41–50.CrossRef
31.
go back to reference Iseki K. The Okinawa screening program. J Am Soc Nephrol. 2003;14 Suppl 2:S127–30.CrossRef Iseki K. The Okinawa screening program. J Am Soc Nephrol. 2003;14 Suppl 2:S127–30.CrossRef
32.
go back to reference National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease. Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 Suppl 1:S170–212. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease. Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 Suppl 1:S170–212.
33.
go back to reference Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.CrossRef Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–54.CrossRef
34.
go back to reference Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. J Am Soc Nephrol. 2006;69:2155–61. Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in the community-dwelling elderly. J Am Soc Nephrol. 2006;69:2155–61.
35.
go back to reference Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 2006;69:375–82.CrossRef Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 2006;69:375–82.CrossRef
36.
go back to reference Iseki K, Iseki C, Ikemiya Y, et al. Risk of developing low GFR or elevated serum creatinine in a screened cohort in Okinawa, Japan. Hypertens Res. 2007;30:167–74.CrossRef Iseki K, Iseki C, Ikemiya Y, et al. Risk of developing low GFR or elevated serum creatinine in a screened cohort in Okinawa, Japan. Hypertens Res. 2007;30:167–74.CrossRef
37.
go back to reference Iseki K, Tozawa M, Iseki C, et al. Demographic trends in the Okinawa Dialysis Study (OKIDS) registry (1971–2000). Kidney Int. 2002;61:668–75.CrossRef Iseki K, Tozawa M, Iseki C, et al. Demographic trends in the Okinawa Dialysis Study (OKIDS) registry (1971–2000). Kidney Int. 2002;61:668–75.CrossRef
Metadata
Title
Proteinuria and decreased body mass index as a significant risk factor in developing end-stage renal disease
Authors
Kunitoshi Iseki
Kaori Tokashiki
Chiho Iseki
Kentaro Kohagura
Kozen Kinjo
Shuichi Takishita
Publication date
01-10-2008
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2008
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-008-0061-6

Other articles of this Issue 5/2008

Clinical and Experimental Nephrology 5/2008 Go to the issue